

Unaudited Financial Statements for the Year Ended 30 September 2020

for

De Novo Pharmaceuticals Limited

Contents of the Financial Statements
for the Year Ended 30 September 2020

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

De Novo Pharmaceuticals Limited

Company Information
for the Year Ended 30 September 2020

DIRECTORS:

Mr F Fahid
Mr A Agarwal

SECRETARY:

Mr T Bunn FCMA

REGISTERED OFFICE:

Maypole Cottage
Lower Green
Wimbish
Saffron Walden
Essex
CB10 2XH

REGISTERED NUMBER:

03761178 (England and Wales)

Balance Sheet
30 September 2020

	Notes	2020 £	2019 £
CURRENT ASSETS			
Debtors	5	30	30
Cash in hand		35,315	5,941
		<u>35,345</u>	<u>5,971</u>
CREDITORS			
Amounts falling due within one year	6	329	150
NET CURRENT ASSETS		<u>35,016</u>	<u>5,821</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>35,016</u>	<u>5,821</u>
CAPITAL AND RESERVES			
Called up share capital		412,563	412,563
Share premium		21,750,836	21,750,836
Retained earnings		(22,128,383)	(22,157,578)
		<u>35,016</u>	<u>5,821</u>

The Company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2020.

The members have not required the Company to obtain an audit of its financial statements for the year ended 30 September 2020 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the Company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the Company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the Company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 14 April 2021 and were signed on its behalf by:

Mr F Fahid - Director

Notes to the Financial Statements
for the Year Ended 30 September 2020

1. **STATUTORY INFORMATION**

De Novo Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. **ACCOUNTING POLICIES**

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets

Acquired intellectual property is included at cost and depreciated in equal annual instalments over a period of 10 years which is its estimated useful economic life. Provision is made for any impairment.

Research and development

Expenditure on research and development is written off in the year in which it is incurred.

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

3. **EMPLOYEES AND DIRECTORS**

The average number of employees during the year was NIL (2019 - NIL).

4. **INTANGIBLE FIXED ASSETS**

	Other intangible assets £
COST	
At 1 October 2019	
and 30 September 2020	469,840
AMORTISATION	
At 1 October 2019	
and 30 September 2020	469,840
NET BOOK VALUE	
At 30 September 2020	-
At 30 September 2019	-

5. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2020 £	2019 £
Other debtors	30	30

Notes to the Financial Statements - continued
for the Year Ended 30 September 2020

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Trade creditors	179	-
Other creditors	<u>150</u>	<u>150</u>
	<u>329</u>	<u>150</u>

7. RELATED PARTY DISCLOSURES

Throughout the year the Company was controlled by Merlin Residual Investments Limited, by virtue of its majority holding in the issued share capital of the Company.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.